相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase 3 Trials of Solanezumab for Mild-to-Moderate Alzheimer's Disease
Rachelle S. Doody et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Successes and Failures for Drugs in Late-Stage Development for Alzheimer's Disease
Camryn Berk et al.
DRUGS & AGING (2013)
Alzheimer's disease market: hope deferred
Zelicia Gerald et al.
NATURE REVIEWS DRUG DISCOVERY (2013)
Deep brain stimulation in dementia-related disorders
Sarah Hescham et al.
NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS (2013)
Long-Term Treatment of Thalidomide Ameliorates Amyloid-Like Pathology through Inhibition of β-Secretase in a Mouse Model of Alzheimer's Disease
Ping He et al.
PLOS ONE (2013)
Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy
Alireza Atri et al.
ALZHEIMERS RESEARCH & THERAPY (2013)
Increased Cerebral Metabolism After 1 Year of Deep Brain Stimulation in Alzheimer Disease
Gwenn S. Smith et al.
ARCHIVES OF NEUROLOGY (2012)
Intranasal Insulin Therapy for Alzheimer Disease and Amnestic Mild Cognitive Impairment A Pilot Clinical Trial
Suzanne Craft et al.
ARCHIVES OF NEUROLOGY (2012)
Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
Vladimir Coric et al.
ARCHIVES OF NEUROLOGY (2012)
Tau elevations in the brain extracellular space correlate with reduced amyloid-β levels and predict adverse clinical outcomes after severe traumatic brain injury
Sandra Magnoni et al.
BRAIN (2012)
Solanezumab for the treatment of mild-to-moderate Alzheimer's disease
Bruno P. Imbimbo et al.
EXPERT REVIEW OF CLINICAL IMMUNOLOGY (2012)
A multimodal RAGE-specific inhibitor reduces amyloid β-mediated brain disorder in a mouse model of Alzheimer disease
Rashid Deane et al.
JOURNAL OF CLINICAL INVESTIGATION (2012)
The Microtubule-Stabilizing Agent, Epothilone D, Reduces Axonal Dysfunction, Neurotoxicity, Cognitive Deficits, and Alzheimer-Like Pathology in an Interventional Study with Aged Tau Transgenic Mice
Bin Zhang et al.
JOURNAL OF NEUROSCIENCE (2012)
An Effector-Reduced Anti-β-Amyloid (Aβ) Antibody with Unique Aβ Binding Properties Promotes Neuroprotection and Glial Engulfment of Aβ
Oskar Adolfsson et al.
JOURNAL OF NEUROSCIENCE (2012)
PF-04494700, an Oral Inhibitor of Receptor for Advanced Glycation End Products (RAGE), in Alzheimer Disease
Marwan N. Sabbagh et al.
ALZHEIMER DISEASE & ASSOCIATED DISORDERS (2011)
T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice
Tetsuo Fukushima et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2011)
Tau as a Therapeutic Target for Alzheimer's Disease
A. Boutajangout et al.
CURRENT ALZHEIMER RESEARCH (2011)
EHT0202 in Alzheimer's Disease: A 3-Month, Randomized, Placebo-Controlled, Double-Blind Study
B. Vellas et al.
CURRENT ALZHEIMER RESEARCH (2011)
The Diabetes Drug Liraglutide Prevents Degenerative Processes in a Mouse Model of Alzheimer's Disease
Paula L. McClean et al.
JOURNAL OF NEUROSCIENCE (2011)
RG3487, a Novel Nicotinic alpha 7 Receptor Partial Agonist, Improves Cognition and Sensorimotor Gating in Rodents
Tanya L. Wallace et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2011)
Solanezumab was safe and well-tolerated for Asian patients with mild-to-moderate Alzheimer's disease in a multicenter, randomized, open-label, multi-dose study
Taro Goto et al.
Alzheimers & Dementia (2010)
PBT2 Rapidly Improves Cognition in Alzheimer's Disease: Additional Phase II Analyses
Noel G. Faux et al.
JOURNAL OF ALZHEIMERS DISEASE (2010)
Epothilone D Improves Microtubule Density, Axonal Integrity, and Cognition in a Transgenic Mouse Model of Tauopathy
Kurt R. Brunden et al.
JOURNAL OF NEUROSCIENCE (2010)
11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study
Juha O. Rinne et al.
LANCET NEUROLOGY (2010)
Can Alzheimer disease be prevented by amyloid-β immunotherapy?
Cynthia A. Lemere et al.
NATURE REVIEWS NEUROLOGY (2010)
An update on treatment and prevention strategies for Alzheimer's disease
Judith Neugroschl et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2009)
Nicotinic receptor agonists and antagonists increase sAPPα secretion and decrease Aβ levels in vitro
M. Mousavi et al.
NEUROCHEMISTRY INTERNATIONAL (2009)
Protection of synapses against Alzheimer's-linked toxins: Insulin signaling prevents the pathogenic binding of Aβ oligomers
Fernanda G. De Felice et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Methylene blue delays cellular senescence and enhances key mitochondrial biochemical pathways
Hani Atamna et al.
FASEB JOURNAL (2008)
Alzheimer disease in the US population - Prevalence estimates using the 2000 census
LE Hebert et al.
ARCHIVES OF NEUROLOGY (2003)
Antibodies against β-amyloid slow cognitive decline in Alzheimer's disease
C Hock et al.
NEURON (2003)
Advanced glycation end products and receptor for advanced glycation end products in AA amyloidosis
C Röcken et al.
AMERICAN JOURNAL OF PATHOLOGY (2003)
分享论文
